Moderna Wins FDA Approval for First mRNA Flu Vaccine, Stock Response Muted

The FDA approved Moderna's seasonal flu vaccine, marking the first mRNA-based flu shot authorized in the U.S. Despite this milestone signaling potential post-pandemic growth, investor reaction remained tepid with shares showing mixed performance.